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Background: Breast cancer is one of the leading causes of cancer deaths. Triple-negative breast cancer (TNBC), an
immunophenotype defined by the absence of immunolabeling for estrogen receptor (ER), progesterone receptor
(PR) and HER2 protein, has a highly aggressive behavior. A subpopulation of TNBCs exhibit a basal-like morphology
with immunohistochemical positivity for cytokeratins 5/6 (CK5/6) and/or epidermal growth factor receptor (EGFR),
and have a high incidence of BRCA (breast cancer susceptibility) mutations. Feline mammary adenocarcinomas
(FMAs) are highly malignant and share a similar basal-like subtype. The purpose of this study was to classify FMAs
according to the current human classification of breast cancer that includes evaluation of ER, PR and HER2 status
and expression of basal CK 5/6 and EGFR. Furthermore, we selected triple negative, basal-like FMAs to screen for
BRCA mutations similar to those described in human TNBC.
Methods: Twenty four FMAs were classified according to the current human histologic breast cancer classification
including immunohistochemistry (IHC) for ER, PR HER2, CK5/6 and EGFR. Genetic alteration and loss of
heterozygosity of BRCA1 and BRCA2 genes were analyzed in triple negative, basal-like FMAs.
Results: IHC for ER, PR and HER2 identified 14 of the 24 (58%) FMAs as a triple negative. Furthermore, 11of these
14 (79%) triple negative FMAs had a basal-like subtype. However, no genetic abnormalities were detected in BRCA1
and BRCA2 by direct sequencing and loss of heterozygosity analysis.
Conclusion: FMAs are highly aggressive neoplasms that are commonly triple negative and exhibit a basal-like
morphology. This is similar to human TNBC that are also commonly classified as a basal-like subtype. While
sequencing of a select number of triple negative, basal-like FMAs and testing for loss of heterozygosity of
BRCA1 and BRCA2 did not identify mutations similar to those described in human TNBC, further in-depth
evaluation is required to elucidate a potential role of BRCA in the tumorigenesis of triple negative, basal-like
FMAs. The strong similarities in clinical behavior, morphology and IHC phenotype suggest that triple negative,
basal-like FMAs may be a suitable spontaneous animal model for studying novel therapeutic approaches
against human basal-like TNBC.
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Breast cancer is the most common neoplasm in women,
with approximately 230,480 new cases and 39,520
deaths occurring in 2011 in the United States [1]. The
disease is complicated by its diverse pathogenesis, and
by large phenotypic variations. Classification systems
based entirely on morphologic criteria are yielding to
new classifications based that also include molecular
and immunophenotypic markers [2] to more accurately
diagnose and prognostic breast cancer. The most recent
classification system classifies human breast cancers
into at least five prognostically significant subtypes,
including estrogen receptor-positive luminal A and B
subtypes, HER2 overexpression subtype, normal breast-
like and basal-like subtype [3]. A variety of immunohis-
tochemical markers have been proposed to define a
basal-like subtype [4,5]. Expression of one or more high
molecular weight basal cytokeratins (CK5/6, CK14, and
CK-17) and/or epidermal growth factor receptor (EGFR)
are most commonly accepted to identify basal-like
differentiation [6]. Furthermore, a large percentage of
basal-like breast cancers lack expression of estrogen
receptor (ER) and progesterone receptor (PR), as well
as HER2 (‘triple negative’ immunophenotype) [7]. While
basal-like breast cancer has the worst clinical outcome
measured in time to development of distant metastasis
[8], there is still some controversy on the histologic
classification of this subtype regarding whether triple
negative status is required for making the diagnosis of
basal-like carcinoma. Some investigations have indicated
that 77% of basal-like breast cancers are triple negative
(TNBC) and 71%-91% of TNBC have basal-like phenotype
[9]. Research has focused especially on TNBC since
they tend to have a poor prognosis with a high risk of
distant metastasis and death within the first 3–5 years
after the diagnosis [10] and no effective treatment is
currently available. Furthermore, TNBC have a high in-
cidence in younger, premenopausal patients with higher
prevalence in African-American women, and are asso-
ciated with germ-line BRCA1 mutations [11].
Feline mammary tumors are the third most common
tumors in the cat, and most tumors are malignant.
Feline mammary tumors are predominantly adenocar-
cinomas [12], with sarcomas and other non-epithelial
tumors occurring less frequently. Feline mammary adeno-
carcinomas (FMAs) are most commonly classified as
in-situ or invasive carcinomas, the latter consisting of
tubulopapillary, cribriform and anaplastic types. Less
common varieties include spindle cell carcinoma, lipid
rich carcinoma, mucinous carcinoma and tumors with
squamous differentiation [13]. However, little work has
been done to characterize feline mammary tumors
based on new concepts of breast cancer classification
as applied to human tumors.Various parameters have been applied for prognosti-
cation of FMAs including the size of tumors, histological
grading, lymph node involvement, and expression of
proliferation markers [14]. Due to the similarities between
human breast cancer and FMAs in regard to epidemiology,
clinical behavior, pattern of metastasis, and histological
features, various studies have been suggested that FMAs
are a potential model of human breast cancer [15,16].
Aberrant expression of hormonal receptors ER and
PR and overexpression of HER2 have also been described
in feline mammary tumors. The majority of feline
mammary tumors are ER-negative [17] and lack HER2
overexpression [18]. In addition, the majority of feline
mammary carcinomas are ER- and PR-negative as studied
by ligand-binding assay [19,20] as well as by immunohis-
tochemistry [21-23]. Controversy exists with respect to
the proportion that express HER2 [18,24,25]. However,
only a few studies have evaluated feline mammary tumors
as a potential model for human TNBC [26].
In humans, breast cancer-susceptibility 1 (BRCA1)
and breast cancer-susceptibility 2 (BRCA2) genes have
been found to be mutated in a large number of early-
onset breast or ovarian cancers [27,28]. Somatic loss of
heterozygosity (LOH), which is the loss of a normal
functioning allele at the heterozygous locus, is one of
the genetic alterations associated with breast cancer
initiation and progression [29]. Especially in patients
that carry germ line mutations in tumor suppressor
genes such as BRCA1 or BRCA2, acquired LOH of the
wild-type allele, corresponding to recessive loss-of-func-
tion mutations, will lead to hereditary breast cancer [30].
Studies in humans have shown that breast cancer with
BRCA1 mutations and less commonly BRCA2 mutations
display predominantly a triple negative immunophenotype
with distinct basal-like subtype [31,32]. More than 75%
of tumors arising in women carrying a BRCA1 mutation
display a triple-negative immunophenotype, a basal-like
subtype, or both [33].
In the current study, a series of twenty four feline
mammary adenocarcinomas were evaluated according to
the current human histologic breast cancer classification,
and the TNBC immunophenotype and basal-like subtypes
were identified by immunohistochemical expression of
ER, PR, and HER2, as well as basal cytokeratins CK5/6
and EGFR. In addition the histologic growth pattern,
tumor grade, presence of necrosis, presence of micro-
calcification, and lymphocytic reaction associated with
the tumor were evaluated. Further investigation of gen-
etic alteration and loss of heterozygosity in BRCA1 and
BRCA2 were conducted in feline triple negative, basal-
like mammary adenocarcinomas to determine whether
the presence of BRCA1/BRCA2 mutations was associ-
ated with this phenotype similar to the observations in
human breast cancer.
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Cases
Twenty four cases of feline mammary adenocarcinomas
were retrieved from the archives of the Diagnostic
Center for Population and Animal Health at Michigan
State University. All cases had been submitted over a
3 year time span from 01/01/2004 until 12/12/2007.
Biopsy samples from 24 cats were included in the
study based on a previously confirmed histopatho-
logical diagnosis of FMAs, sufficient archival material in
high quality (absence of extensive necrosis or autolysis)
and histologically unremarkable mammary tissue in the
same or in additional paraffin blocks. Mean age at the
time of diagnosis was 12 years (range, 6 to 19 years). Of
the 24 cats, 18 were spayed female, 4 were intact
female, 1 was castrated male, and 1 was of unidentified
gender. These cases represented approximately 80% of
malignant feline mammary tumors over the archival
time span.
Histological grading
Representative formalin-fixed paraffin-embedded tissue
blocks were recut at a thickness of 4 microns and were
stained routinely with hematoxylin and eosin for histologic
evaluation. Tumors were histopathologically classified
according to the World Health Organization (WHO)
[13], and the three most predominant growth patterns
were recorded. Tumor grading was performed by the
Nottingham modification of the Scarff-Bloom-Richardson
grading system as reported by Elston and Ellis [34].
Briefly, this method assigns a score of 1, 2 or 3 for each of
three histologic or cytologic features, including nuclear
grade, extent of tubule formation and mitotic rate per 10
high power fields (0.44 mm2 field diameter). The scores
for each of these parameters are then summed to assign
the tumor grade, with scores of 3, 4 or 5 considered grade
I, 6 and 7 grade II, and 8 and 9 grade III.
The presence or absence of tumor necrosis was noted,
and the presence or absence of calcium hydroxyapatite
microcalcifications, detected as distinct purple densities
visible with light microscopy on H&E staining, was
recorded. Specimens were also polarized to evaluate for
possible calcium oxalate microcalcifications, an optically
clear but refractile form of microcalcification not usually
demonstrable by routine light microscopy.
Tumors were also evaluated for the presence of asso-
ciated lymphocytic infiltration, recorded by location as
peritumoral or intratumoral. Lymphocytic infiltrates were
scored as 0 (negligible or absent infiltration), 1+ (few
lymphoid aggregates associated with tumor), 2+ (mod-
erate lymphoid aggregates or infiltrates typically seen in
20 to 50% of the tumor), or 3+ (brisk lymphoid aggre-
gates or infiltrates associated with more than 50% of
the tumor).Immunohistochemistry
Serial sections of each tumor were immunohistochem-
ically labeled for ER using the CONFIRM anti-ER (SP1)
rabbit monoclonal antibody, and for PR using the
CONFIRM anti-PR (1E2) rabbit monoclonal antibody
(both Ventana Medical Systems, Inc, Tucson, AZ). The
antibodies were applied for 32 minutes at 37°C for ER,
and at 16 minutes at 37°C for PR according to vendor
protocol, using the Ventana BenchMark XT automated
immunostainer with the Ventana iView detection Kit
(Ventana Medical Systems, Inc, Tucson, AZ). ER and PR
immunohistochemical labeling was evaluated by recording
labeling intensity, location and estimated percentage of
positive cells, based on evaluation of a minimum of twenty
high power (400×) fields. Labeling intensity was recorded
as 0 (no labeling), 1+ (weak labeling above background),
2+ (moderate labeling), or 3+ (strong labeling) as previ-
ously described [17].
Additional sections were also labeled for HER2 using
the PATHWAY anti-HER2/neu rabbit monoclonal anti-
body directed against the internal domain of the c-erbB-2
oncoprotein (Ventana Medical Systems, Inc, Tucson,
AZ). The antibody was applied for 32 minutes at 37°C
according to vendor protocol using the Ventana Bench-
Mark XT automated immunostainer with iView Detection
Kit (Ventana Medical Systems, Inc, Tucson, AZ). Im-
munohistochemical labeling for HER2 was evaluated
according to the HercepTest™, recording labeling intensity
and location, and estimated percentage of positive cells,
also based on a minimum of twenty high power (400×)
fields. Specifically, labeling intensity was recorded as 0
(no labeling), 1+ (weak, incomplete membranous labeling),
2+ (moderate, complete membranous labeling), or 3+
(strong, complete membranous labeling) as previously
described [17]. Scores 2 and 3 were considered to indi-
cate overexpression, scores 0 and 1 were considered as
negative.
To evaluate tumors for features of basal-like subtype,
additional sections were immunolabeled for CK5/6 (clone
EP1601Y; Cell Marque, Rocklin, Ca), and for epidermal
growth factor receptor (Ventana CONFIRM anti-EGFR
(5B7) rabbit monoclonal primary antibody (Ventana
Medical Systems, Inc, Tucson, AZ), both applied for
16 minutes at 37°C also according to vendor protocol
using the Ventana BenchMark XT automated immu-
nostainer with iView Detection Kit (Ventana Medical
Systems, Inc, Tucson, AZ). For CK5/6 and EGFR, sections
were also evaluated for labeling intensity and location
and estimated percentage of positive cells, with labeling
intensity recorded as 0 (no labeling), 1+ (weak labeling),
2+ (moderate labeling), or 3+ (strong, intense labeling) [4].
Feline uterus sections were used as positive controls
for ER and PR, and a human breast carcinoma was
used as positive control for over-expression of HER2.
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positive controls for CK5/6 and EGFR. For negative con-
trols the primary antibodies were replaced by homologous
non-immune sera. All positive and negative controls gave
the expected features in all of the evaluation.
DNA isolation and amplification of BRCA1 and BRCA2
Genomic DNA extracted from paraffin-embedded tissue
sections obtained from 11 samples of triple negative, basal-
like subtype adenocarcinomas was amplified of normal
and tumor tissue following a published protocol [35].
To select population of neoplastic cells from basal-like
tumors, immunohistochemistry for CK5/6 and EGFR were
used to locate the basal-like subtype area, and only
immunopositive non-necrotic areas were collected for
DNA extraction. Primers were designed to detect BRCA1
and BRCA2 mutations according to mutations reported
by Musolino et al., 2007 [36]. PCR product was visualized
on agarose electrophoresis and submitted for both di-
rections sequencing at the Research Technology Sup-
port Facility (RTSF), MSU. Sequences were determined
on an ABI PRISM® 3730 Genetic Analyzer (Applied
Biosystem, CA). Twenty five genomic DNA samples
extracted from normal skin collected at routine necropsy
from 25 cats that had diseases unrelated to cancer were
used as control.
Evaluation of loss of heterozygosity in BRCA 1and BRCA2
Loss of heterozygosity (LOH) at the BRCA1 and BRCA2
loci was evaluated by using M13-labeling PCR amplifica-
tion of microsatellite markers at the 5′ and 3′ of both
genes. Microsatellites from normal and tumor DNA were
amplified using PCR with M13 tailed primers. The for-
ward primer for each primer pair was synthesized with
an additional modified 20-bp M13 tailed added to the
5′end. An M13 primer that has the same sequence and
that directly labelled to the fluorescence, 6-FAM, was
used as a label primer for the detection [37]. Standard
PCR reactions were prepared in a 25-μl total volume
using 1 μl extracted DNA, 5 pmol of labeled M13
primer, 0.5 pmol of M13 tailed forward primer, 5 pmol
unlabeled reverse primer, and 0.625 U of GoTaq® DNA
polymerase (Promega, Madison, WI). Cycling conditions
were as follows: 40 cycles at 95°C for 1 minute, 59°C
for 2 minute, and 72°C for 3 minute; and 72°C for 5 mi-
nutes. Amplified products were analyzed by agarose gel
electrophoresis on a 2% agarose gel. Fluorescence vis-
ualization was performed using Typhoon 9200 Variable
Mode Image (GE Healthcare, Pittsburgh, PA). PCR prod-
ucts were further submitted for sequencing using capillary
electrophoresis on an ABI PRISM® 3130 Genetic Analyzer
(Applied Biosystems, CA). Allelic imbalance was deter-
mined using the normalized allelic ratio equation [LOH
ratio = (D1)(N2)/(D2)(N1)], where D1 and D2 are theheights of the smaller and larger allelic peaks, respectively,
fromthe duct and N1 and N2 are the heights of the allelic
peaks from surrounded normal tissue DNA [38]. Allelic
imbalance was noted if the area under the target size peak
in the basal-like tumor DNA was altered (increase or
decrease) by 50% or more, after compared to peak area
in the surrounding non-tumor DNA. Samples showing




On histopathologic review (Table 1), 3 of the 24 FMAs
were fairly pure papillary carcinomas with well-defined
papillary structures identified through a majority of the
tumors. The remaining 21 FMAs showed a variety of
growth patterns. Most displayed admixed components of
tubulopapillary, cribriform and solid growth patterns. In
addition, cystic areas were common and were seen in
seven of the cases.
According to the histologic characteristics, the FMAs
had a low nuclear grade in 3 cases, an intermediate
nuclear grade in 12 cases and a high nuclear grade in 9
cases. There was scant tubule formation in 3 cases,
intermediate tubule formation in 10 cases and prominent
tubule formation in 11 cases. Only one FMA had an
intermediate mitotic rate, with 23 having high mitotic
rates (>10 figures). In fact, the mitotic rate was typically
very high with a mean mitotic rate of 33 and a median
of 27 mitoses per 10 high power fields (0.44 mm2 field
diameter). Based on the overall tumor grade according to
the combined scores for nuclear grade, tubule formation
and mitotic rate, 2 FMAs were well differentiated (grade
1) tumors, 15 moderately differentiated (grade II) tumors,
and 7 poorly differentiated (grade 3).
Tumor necrosis was common, with 21 of the 24 FMAs
exhibiting significant (>10%) areas of necrosis, whereas 3
adenocarcinomas were devoid of significant necrosis.
Microcalcifications were identified within only 2 FMAs,
with the other 22 FMAs having no microcalcifications.
In both of the cases with microcalcification, the deposits
were identified by light microscopy, representing calcium
hydroxyapatite. Polarized light microscopy showed no
additional calcium oxalate microcalcifications in any of
the tumors examined. Lymphocytic infiltrates associated
with tumor were present in 15 of the 24 (62.5%) FMAs,
and all had a 1+ to 2+ peritumoral distribution.
Immunohistochemistry-based molecular
subtype classification
Estrogen receptor labeling was present in 2 of the 24
FMAs (8.3%) (Table 2). Labeling was weak (1+) and was
present in 10% and 40% of the tumor nuclei respectively.
Progesterone receptor labeling (Table 2) was present in
Table 1 Histologic characteristics of feline mammary adenocarcinomas
Case Patterns* Nuclear grade % Tubules Mitoses/ 10 HPF Grade Necrosis Micro-calcifications Lymphocytie infiltrates**
1 CY, SO, CR 2 60 45 2 Y N PT 1
2 SO, TU 2 80 47 2 Y N 0
3 TU, SO, PA 2 70 54 2 Y N PT 2
4 TU, PA 1 80 7 1 Y Y PT 1
5 TU, SO 2 70 65 2 Y N PT 1
6 SO, TU, CY 2 50 48 2 Y N 0
7 SO, PA 3 5 20 3 N N PT 2
8 TU, CR 2 90 12 2 Y N 0
9 SO, CY 3 5 56 3 Y N PT 1
10 TU, SO, CY 3 80 22 3 Y N PT 1
11 TU 3 90 25 2 Y N PT 1
12 TU, SO 3 75 18 2 Y N PT 1
13 SO, CY 3 10 28 3 Y N 0
14 TU, SO 3 60 70 3 N N 0
15 TU 3 90 25 2 Y N PT 1
16 CY, TU 2 70 62 2 Y Y 0
17 PA 2 90 12 2 Y N 0
18 TU, SO 2 70 45 2 Y N 0
19 PA 1 90 12 1 N N 0
20 PA, TU, CY 2 80 42 2 Y N PT 2
21 PA 2 90 24 2 Y N PT 2
22 SO, TU 2 20 12 2 Y N PT 1
23 TU, PA 3 70 52 3 Y N PT 1
24 SO, CY 3 5 90 3 Y N PT 2
*CY cystic, SO solid, TU tubular, PA papillary.
**PT peritumoral.
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weak (1+) in 5 cases, moderate (2+) in 1 case, and strong
(3+) in 1 case, with positive nuclei ranging from 5% to
90%, the latter in the case with strong nuclear labeling.
No cases expressed both estrogen and progesterone
receptors. HER2 was overexpressed in 4 of the 24
FMAs (Table 2). Labeling was moderate (2+) in all four
cases, two with 20% and 40% of cells with cytoplasmic/
membrane labeling, one with membranous labeling in
20% of the cells, and one with membranous labeling in
30% of the papillary components. In our series, 14 (58.3%)
tumors were triple negative (ER-, PR-, and HER2-).
Immunolabeling for CK5/6 (Table 2) was identified in
the myoepithelial cells lining normal and hyperplastic
mammary ducts as well as in hair follicles and portions
of epidermal tissues, these structures serving as internal
controls. Of the 24 FMAs 17 (71%) had uniformly strong
(3+) positive labeling of tumor cells (Figure 1B); 11 of
these had 50% or more positive tumor cells, the other 6
cases showing similar strong labeling that varied from
5% to 40% of positive tumor cells. For 17 positive cases,labeling was seen in an average of 63% of the tumor
cells. In 2 of the cases, with 20% and 30% positive tumor
cells, the pattern appeared clonal, with intense reaction
in only a portion of the tumor. In the other cases, the
labeling was irregular and diffuse throughout the tumors.
Immunolabeling for EGFR (Table 2) similarly showed
moderate to strong positive (2 + −3+) labeling in myo-
epithelial cells of normal and hyperplastic ducts and in
incidental sebaceous glands, these again serving as in-
ternal controls. Of the 24 FMAs 15 (62.5%) had EGFR
positive tumor cells (Figure 1C) with weak (1+) labeling
in 9 cases (60%) and moderate (2+) labeling in 6 cases
(40%). The labeling was membranous in distribution
with 9 cases showing some degree of cytoplasmic label-
ing as well. Immunolabeling was observed in 50% or
more of the tumor cells in 7 cases (47%), with 9 FMAs
having 5% to 30% positive tumor cells. For the positive
cases labeling was seen in an average of 41% of the
tumor cells. Positive labeling appeared diffuse and
irregular in the tumors, without the clonal pattern
noted in two of the cases when labeled with CK5/6.
Table 2 Immunohistochemical staining results of ER/PR/HER2, CK5/6, and EGFR
ER PR HER2 CK5 EGFR
Case Intensity Location Percent Intensity Location Percent Intensity Location Percent Intensity Location Percent Intensity Location Percent
1 0 1 N* 5 0 3 M, C* 100 0
2 0 0 0 3 M, C 100 0
3 0 0 2 C, M 20 3 M 20 2 C, M 80
4 1 N 40 0 2 M 20 3 M 100 2 M 15
5 1 N 10 0 0 3 M 30 2 M 50
6 0 0 0 3 C, M 40 1 M 5
7 0 0 0 3 M, C 80 1 M 60
8 0 0 0 0 0
9 0 0 0 3 C, M 25 1 C, M 30
10 0 1 N 5 0 3 C, M 5 1 C 10
11 0 3 N 90 0 0 0
12 0 2 N 80 0 0 1 M 5
13 0 1 N 10 2 C, M 40 3 M 80 1 M, C 15
14 0 0 0 3 M 100 0
15 0 0 0 3 M, C 70 1 C, M 30
16 0 1 N 30 0 3 M 50 2 C, M 50
17 0 0 0 0 2 M, C 30
18 0 0 0 0 0
19 0 0 0 3 M, C 90 2 M 90
20 0 0 0 3 M 90 1 M 80
21 0 1 N 5 2 M 30 0 0
22 0 0 0 3 M 20 1 C, M 70
23 0 0 0 0 0
24 0 0 0 3 M 70 0
*N nuclear, C cytoplasmic, M membranous.


















Figure 1 Identification of triple negative basal-like subtype (ER-, HER2-, CK5/6+ and/or EGFR+). Sections of feline mammary
adenocarcinoma with basal-like (A) subtype were CK5/6 (B)and EGFR positive (C), but negative for estrogen receptor (D), progesterone receptor
and HER2).
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CK5 and EGFR, while 6 (25%) were positive for either
CK5/6 or EGFR; the remaining 5 cases (21%) were
negative for both CK5/6 and EGFR.
Based on expression of ER, PR, HER2, CK5/6, and
EGFR, tumor subtypes were immunohistochemically clas-
sified as estrogen receptor-positive luminal A (ER+, PR +
or PR-, HER2-), estrogen receptor-positive luminal B
(ER+, PR + or PR-, HER2+), HER2 overexpression (ER-,
PR + or PR-, HER2+), and basal-like (CK5/6+ and/or
EGFR+). In our series, the distribution of tumor molecular
subtypes was: 1 (4.2%) estrogen receptor-positive luminal
A (case 5 in Table 2, Figure 2A-D), 1 (4.2%) estrogen
receptor-positive luminal B (case 4 in Table 2, Figure
3A-D), 1 (4.2%) HER2 overexpression (case 3 in Table
2, Figure 4A-D), and 19 (79.2%) basal-like (Table 2,
Figure 1A-D).
Detection of TNBC with basal-like subtype
Eleven of the 14 FMAs (79%) that were negative for
estrogen receptor, progesterone receptor and HER2
(triple negative) exhibited a basal-like subtype, 7 ofFigure 2 Identification of estrogen receptor-positive luminal A subtyp
adenocarcinoma with tubular (A) and solid morphology were estrogen re
EGFR (D).these 14 FMAs were positive for both CK5/6 and EGFR,
and four were positive for either CK5/6 or EGFR. Eight of
the 24 FMAs (33%) were positive for either CK5/6 or
EGFR or both, but had positive labeling for at least
one of the following: HER2 (1 case), estrogen receptor
(1 case), progesterone receptor (4 cases) or multiple
receptors (2 cases), thereby precluding assignment of
these tumors as true basal-like subtype TNBCs.
Genetic analysis
Further investigation of genetic alterations in BRCA1
and BRCA2 was performed. Only five of the 11 DNA
samples from TNBCs with basal like subtype could be
amplified. Examination of BRCA1/BRCA2 sequences
revealed missense mutations and polymorphisms, but
there were no mutations or polymorphisms specific to
the tumors compared to normal feline DNA. No abnor-
mality in BRCA1 and BRCA2 alleles was detected (Figure 5.
Missense mutations and polymorphisms as compared
to the established cat genome (Genome browser: http://
genome.ucsc.edu/) were identified in the BRCA1 or
BRCA2 gene in triple-negative basal-like FMAs. However,e (ER+, PR + or PR-, HER2-). Sections of feline mammary
ceptor positive (B) and HER2 negative (C), but focally positive for
Figure 3 Identification of estrogen receptor-positive luminal B subtype (ER+, PR + or PR-, HER2+). Sections of feline mammary
adenocarcinoma with tubular (A) and papillary morphology were estrogen receptor positive (B) and HER2 positive (C), but positive for CK5/6 (D).
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and were also identified in control DNA obtained from
normal cats.
Discussion
This study was designed to investigate FMAs as a potential
natural model for human basal-like TNBC. FMAs are
typically aggressive with a significant propensity to
metastasize and usually exhibit morphological features
similar to human breast cancer; as such, they have been
proposed as a model for human breast cancers [15,16].
Using the WHO classification, the majority of the cases
in our series were adenocarcinomas with predominant
tubulopapillary and solid features. Of interest, cystic
change was common and was seen in 33% of adenocar-
cinomas. When applying the Nottingham grading system
that is widely accepted in human breast cancer, FMA
grading was strongly influenced by generally high mitotic
rates which averaged 37 mitoses, with a range of 7 to 90
per 10 high power fields (0.44 mm2 field diameter). In fact
29% of the FMAs had greater than 50 mitotic figures per
10 high power fields. This finding reflects the generallyFigure 4 Identification of HER2 overexpression subtype (ER-, HER2+).
papillary (A) and solid morphology were estrogen receptor negative (B) anrapid growth that these tumors display. The distribution
of 8% well differentiated, 50% moderately differentiated,
and 42% poorly differentiated adenocarcinomas correlates
well with a previous series of 55 FMAs [39] in which 14%
were well differentiated, 60% were moderately differenti-
ated and 27% were poorly differentiated. In that study, a
good predictive value in relation to prognosis for well and
poorly differentiated tumors was reported. The concord-
ance of our series with the previous series also suggests
that the Nottingham grading system applied to FMAs is
reproducible across collections of cases.
Tumor necrosis is a common finding in rapidly growing
neoplasms, whose growth often outpaces the ability of
angiogenetic pathways to provide adequate vascular
support. Indeed, in our study, with a high mitotic index
in the majority of cases, necrosis was present in all but
3 cases, with those 3 tumors showing 20, 24 and 70 mi-
toses per 10 high power fields respectively. The presence
of necrosis could not be associated with any other specific
morphologic features.
Microcalcifications are often used as a surrogate marker
for human breast cancers [40], allowing detection ofSections of feline mammary adenocarcinoma with tubular and
d HER2 positive (C), but focally positive for CK5/6 (D).
Case 5’ BRCA1 (TC)n 3’ BRCA1 (GAAA)n
Normal Tumor Normal Tumor
#2 No amplification Homozygous Homozygous Homozygous
#7 Heterozygous Heterozygous Heterozygous Heterozygous
#14 Heterozygous Heterozygous Heterozygous Heterozygous
#17 Heterozygous Heterozygous Heterozygous Heterozygous
#22 Heterozygous Heterozygous Heterozygous Heterozygous
Case 5’ BRCA2 (CA)n 3’ BRCA2 (CA)n
Normal Tumor Normal Tumor
#2 No amplification Heterozygous Homozygous Homozygous 
#7 Heterozygous Heterozygous Homozygous Homozygous 
#14 Heterozygous Heterozygous Heterozygous Heterozygous
#17 Heterozygous Heterozygous Homozygous Homozygous 
#22 Homozygous Homozygous Homozygous Homozygous
Figure 5 Detection of loss of heterozygosity in BRCA1 and BRCA2. No allelic losses were detected in triple negative tumors exhibiting a
basal-like phenotype.
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radiographic densities associated with these dystrophic
calcifications. In human breast cancer, the majority of
these represent calcium hydroxyapatite precipitates, which
are readily identified by light microscopy with H&E
staining. A second form of microcalcification composed
of calcium oxalate accounts for up to 10% of cases with
microcalcifications and is readily identified by polarization
[41]. In our series, only two of the cases had calcium
hydroxyapatite microcalcifications within the tumor,
with no cases having calcium oxalate by polarized light
microscopy. The relative lack of microcalfications in
FMAs compared to human carcinomas may represent a
species variation.
Lymphocytic infiltration was a common finding with
62.5% of the FMAs showing peritumoral infiltrates.
Similarly, lymphocytic infiltration is not uncommon in
human TNBCs, particularly in the basal-like subtype
that was also overrepresented in this case series.
Estrogen and progesterone receptors are commonly
expressed in human breast cancers, with ER expression
being noted in 70-80% of cases [42]. However, about
15-20% of breast cancers in humans are negative for
both ER and PR, typically in more poorly differentiated
tumors [42]. Previous studies of FMAs have shown that
ERs are expressed at much lower rates in FMAs and
expression of PRs tends to slightly lower than in
humans, but significantly higher than ER expression in
most studies. In one study of 42 feline mammarycarcinomas, 4 tumors (9.5%) were positive for ER by
IHC while 28 tumors (66.7%) were positive for PR [21].
In a second similar study 6 of 27 tumors (22%) were
positive for ER and this number correlated well with
ER levels evaluated by a dextran-charcoal method [22].
Another study specifically compared ER and PR expression
and found 5 of 25 cases (20%) of FMAs positive for ER
by IHC and dextran-charcoal methods, and 9 of 25
(36%) of these cases were positive for PR [23]. Assay by
dextran-charcoal method alone yielded similar findings,
with 2 of 20 cases (10%) positive for ERs [19]. In our
current series only 2 of 24 (8%) of cases were positive
for ER, while 7 of 24 (29%) were positive for PR. Our
data confirm the observation of lower levels of ER com-
pared to PR in FMAs as well as lower ER and PR
expression in FMAs compared to human breast cancer
[20,21,23,42].
HER2 overexpression is seen in about 15-25% of
human breast cancers, and is the basis for therapy with
trastuzumab, an antibody based blocker of the HER2
membrane protein [43]. HER2 overexpression is com-
monly observed in cats with spontaneous feline mam-
mary tumors [18,24,25,44,45], however, the reported
percentages of HER2 overexpression in feline mammary
tumors are highly variable between studies (5.5%-90%).
In our study, 4 of 24 FMAs (17%) were immunopositive
for HER2. Similar percentages (5.5%, 16% and 36%) of
HER2 expression have been reported in some studies
[18,24,25], while two other studies reported significantly
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reported percentages is most likely based on selection of
cases (benign and malignant as well as morphologic
subtypes), technical factors and subjective interpretation.
Variation in genetic backgrounds between different cat
populations, such as incidence of breeds at different
continents, may also contribute to such differences in
reported percentages. Similar controversies regarding
HER2 expression have been reported for human breast
cancer, and the FDA approved HercepTest™ is recom-
mended for an accurate and reliable evaluation of HER
2 expression [25,46]. In this study, the standardized
HercepTest™ was used for HER2 expression analysis
and results were similar (17% versus 16%) to another
study that applied the HercepTest™ scoring system [25].
Immunohistochemistry for ER, PR, and HER2 over-
expression might also be negatively influenced by to
short or prolonged fixation time or delayed fixation
[47,48]. Since our cases represented surgical biopsy
material, such negative influences are unlikely and the
studied cases had been fixed between 24–48 hours
according to recommended fixation times [49,50]. Fur-
thermore, all of the cats in this study were family pets
and most had been neutered/spayed at an early age.
In our study, 14 of the 24 (58%) cases were negative
for ER and PR and for HER2 overexpression. In humans,
such TNBC exhibit aggressive behavior and are further
complicated by the lack of targeted therapy. FMAs ap-
pear to represent a rich source of TNBCs, and could
provide a valuable model for the evaluation of effective
therapeutic strategies for these tumors in humans. In
human breast cancers, basal-like subtype tumors ac-
count for about 50-80% of all TNBC [51], which is
similar to our series of FMAs with 79% of triple nega-
tive tumors exhibiting a basal-like subtype. Of particu-
lar interest, TNBCs include a subset of neoplasms with
a basal-like subtype that are often associated with
BRCA1 mutations and are characterized by expression
of genes usually found in basal or myoepithelial cells of
the normal human breast [52]. Such cases can be iden-
tified by a series of specific surrogate basal markers, in-
cluding CK5/6, CK17, CK14 and EGFR [51]. IHC
expression of CK5/6 and/or EGFR in tumors negative
for both ER and HER2/neu is a pragmatic and widely
accepted method for diagnosing basal-like subtype
TNBC [51].
This study represents an initial attempt to define the
genetic alteration of triple negative FMAs with a basal-
like subtype, in order to determine how this profile may
differ from the genetic profiles of tumor of similar pheno-
type occurring in humans. We found no mutations or
allelic losses in either the BRCA1 or BRCA2 gene. How-
ever only DNA from 5 cats could be amplified from arch-
ival formalin-fixed paraffin embedded material for geneticanalysis. Larger numbers of samples need to be studied
for a more comprehensive understanding of the potential
role of BRCA mutations in FMAs of basal-like phenotype.
It is also possible that epigenetic modifications which lead
to BRCA gene silencing may play a role in these cases.
In addition, since mutations in BRCA1 and BRCA2 were
investigated within the locations reported in human breast
cancer, cats may carry BRCA1 and BRCA2 mutations in
different gene locations.
Conclusion
FMAs have an aggressive biologic behavior, are of high
histologic grade, and a high percentage of these tumors
is triple negative, with about 80% displaying a basal-like
subtype. Previous studies noted that estrogen and pro-
gesterone receptor negative proliferations occur spon-
taneously as purely intraepithelial lesions in feline
mammary glands, and have suggested that these might
be an effective model for evaluating the earliest stages of
hormone receptor negative disease in humans [17]. In
our study, we demonstrated a high incidence of triple
negative basal-like FMAs that have a similar aggressive
clinical behavior as their human counterparts and would
be a valuable natural occurring animal model to study
human TNBCs of basal-like subtype.
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